TEM240816C22500
- 14.79
- 0.000.00%
Tempus AI Newsroom
Riot Platforms & North Face Parent V.F. Corp Are Among 11 Mid-Cap Stocks That Performed The Best Last Week (July 14-July 20): Are Others In Your Portfolio?
Press Release: Tempus to Report Second Quarter 2024 Financial Results on August 6
Tempus AI Shares Climb Following Launch of AI-Enabled Test
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
Tempus Expands Immuno-Oncology Portfolio With Launch of AI-enabled, Multimodal Immune Profile Algorithmic Tests
Investor That Backed Moderna Raises $3.6B For AI-driven Biotech Ventures
Tempus Surpasses 500 Research Publications
Using AI to advance medical care, TempusAI (TEM.US) is favored by Wall Street banks.
Several Wall Street analysts have expressed positive views on TempusAI, a biotechnology company that applies artificial intelligence (AI) to the field of medical care, and expect it to bring sustained revenue.
Buy This Healthcare Company's Stock Because It's an AI Play, Analysts Say
Sector Update: Health Care Stocks Rise in Afternoon Trading
Tempus AI Initiated at Buy by B of A Securities
Tempus AI Down Despite Bullish Starts From Analysts
BofA Securities Initiates Tempus AI(TEM.US) With Buy Rating, Announces Target Price $41
Tempus Could Gain Share In AI Health Care Market Poised To Grow By Over 30%
Express News | Tempus AI Shares Reverse Course, Last Down 6.1%
Tempus AI Poised for 27% Topline Growth Through 2028, Morgan Stanley Says
Wall Street Analysts Bullish on Genetic Testing Firm Tempus AI
AI-boosted Medical Diagnostics Firm Tempus AI Given 'Buy' Rating
Tempus AI Initiated, Helios Downgraded: Wall Street's Top Analyst Calls
Express News | Tempus AI Shares Gain 5.4% After Brokerages Start Coverage With Bullish Ratings